August 29, 2019 09:02 AM EDTUpdated 09:37 AM
R&D

Ab­b­Vie’s $10B Ro­va-T play ends in one last fail­ure — R&D team shuts it all down

John Carroll

Editor & Founder

Ab­b­Vie’s Ro­va-T has failed its last clin­i­cal tri­al.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Out­look's shares crash as wet AMD drug flunks Phase 3 test

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times